JP2023548632A - アルツハイマー病の処置のための組成物および方法 - Google Patents

アルツハイマー病の処置のための組成物および方法 Download PDF

Info

Publication number
JP2023548632A
JP2023548632A JP2023535666A JP2023535666A JP2023548632A JP 2023548632 A JP2023548632 A JP 2023548632A JP 2023535666 A JP2023535666 A JP 2023535666A JP 2023535666 A JP2023535666 A JP 2023535666A JP 2023548632 A JP2023548632 A JP 2023548632A
Authority
JP
Japan
Prior art keywords
fusion protein
tau
protein according
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535666A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022093736A5 (https=
JP2023548632A5 (https=
Inventor
彰徳 菱谷
コヤ，ケイゾウ
Original Assignee
ソラ・バイオサイエンシズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソラ・バイオサイエンシズ・エルエルシー filed Critical ソラ・バイオサイエンシズ・エルエルシー
Publication of JP2023548632A publication Critical patent/JP2023548632A/ja
Publication of JPWO2022093736A5 publication Critical patent/JPWO2022093736A5/ja
Publication of JP2023548632A5 publication Critical patent/JP2023548632A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023535666A 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法 Pending JP2023548632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105472P 2020-10-26 2020-10-26
US63/105,472 2020-10-26
PCT/US2021/056539 WO2022093736A1 (en) 2020-10-26 2021-10-26 Compositions and methods for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2023548632A true JP2023548632A (ja) 2023-11-17
JPWO2022093736A5 JPWO2022093736A5 (https=) 2024-10-30
JP2023548632A5 JP2023548632A5 (https=) 2024-10-30

Family

ID=78676670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535666A Pending JP2023548632A (ja) 2020-10-26 2021-10-26 アルツハイマー病の処置のための組成物および方法

Country Status (8)

Country Link
US (1) US20240025954A1 (https=)
EP (1) EP4232462A1 (https=)
JP (1) JP2023548632A (https=)
CN (1) CN117098771A (https=)
AU (1) AU2021367952A1 (https=)
CA (1) CA3199433A1 (https=)
TW (1) TW202233655A (https=)
WO (1) WO2022093736A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503065A (ja) * 2012-12-21 2016-02-01 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
WO2020169838A1 (en) * 2019-02-21 2020-08-27 Cambridge Enterprise Limited Modular binding proteins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
JP2004502781A (ja) 2000-07-07 2004-01-29 パナシア　ファーマシューティカルズ　インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US12162929B2 (en) 2018-02-19 2024-12-10 New York University Alpha-synuclein single domain antibodies
EP4132955A2 (en) * 2020-04-10 2023-02-15 SOLA Biosciences LLC Compositions and methods for the treatment of protein aggregation disorders
BR112022021604A2 (pt) * 2020-04-28 2022-12-06 Sola Biosciences Llc Composições e métodos para tratamento de proteinopatias associadas à tdp-43

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503065A (ja) * 2012-12-21 2016-02-01 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
WO2020169838A1 (en) * 2019-02-21 2020-08-27 Cambridge Enterprise Limited Modular binding proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
J. PHYS. CHEM. B, vol. 119, JPN6025041593, 2015, pages 4582 - 4593, ISSN: 0005705363 *
NAT. CHEM., vol. 10, no. 2, JPN6025041594, 2018, pages 170 - 176, ISSN: 0005705364 *
NAT. REV. MOL. CELL BIOL., vol. 11, no. 8, JPN6025041595, 2010, pages 579 - 592, ISSN: 0005705365 *
NATURE, vol. 580, JPN6025041591, 2020, pages 326 - 327, ISSN: 0005705361 *
SCIENTIFIC REPORTS, vol. 7, no. 8531, JPN6025041590, 2017, pages 1 - 13, ISSN: 0005705360 *
信州医誌, vol. 56, no. 3, JPN6025041592, 2008, pages 115 - 124, ISSN: 0005705362 *

Also Published As

Publication number Publication date
AU2021367952A1 (en) 2023-06-08
TW202233655A (zh) 2022-09-01
US20240025954A1 (en) 2024-01-25
CA3199433A1 (en) 2022-05-05
EP4232462A1 (en) 2023-08-30
WO2022093736A1 (en) 2022-05-05
CN117098771A (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
JP6293664B2 (ja) 桿体由来錐体生存因子をコードするベクター
US20240327477A1 (en) Compositions and methods for the treatment of tdp-43 proteinopathies
JP7285022B2 (ja) 組換えヒトＩＩ型ミトコンドリアダイニン様ＧＴＰａｓｅの遺伝子配列及びその使用
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
US20230234997A1 (en) Compositions and Methods for the Treatment of Synucleinopathies
US20230226223A1 (en) Compositions and Methods for the Treatment of Protein Aggregation Disorders
US20240400626A1 (en) Compositions and methods for the treatment of p53-mediated cancers
JP2023548632A (ja) アルツハイマー病の処置のための組成物および方法
US20250042958A1 (en) Compositions and methods for the treatment of proteopathies
RU2855933C1 (ru) Композиции и способы для лечения протеинопатий tdp-43
RU2851326C1 (ru) Композиции и способы лечения нарушений агрегации белков
HK40092059A (zh) 用於治疗突触核蛋白病的组合物和方法
HK40088984A (zh) 用於治疗tdp-43蛋白病的组合物和方法
HK40087812A (zh) 用於治疗蛋白聚集障碍的组合物和方法
KR20250156211A (ko) 글루코실세라미다제 베타 1 결핍증과 관련된 신경 장애의 치료를 위한 조성물 및 방법
CN117836420A (zh) 重组tert编码病毒基因组和运载体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260407